Radisys Introduces Programmable Media Analytics to Monetize 5G & Edge Cloud Applications
Radisys® Corporation, a global leader of open telecom solutions, today announced the addition of Engage Media Analytics within the acclaimed Engage Digital Platform (EDP). Engage Media Analytics is a comprehensive solution that provides Communication Service Providers (CSPs), System Integrators, and Enterprises with cost-effective low-code/no-code visual design tools to create Industry 4.0 applications with new AI-powered audio analytics and computer vision capabilities.
Engage Media Analytics’ application possibilities include notifying medical personnel when a patient in a wheelchair needs assistance or an elderly at-home patient has fallen from the bed; or identifying critical keywords or background sounds on an emergency call to augment the live agent discussion and help make life-saving decisions; detecting a fire in a factory, campus building, or other location and alerting emergency services personnel; monitoring retail shelves and combing customer identification, location, and live video to send money saving coupons to a frequent shopper’s phone as they near a location with promotional items; and many other Industry 4.0 services.
The Engage Media Analytics solution offers a unique combination of capabilities:
- Off-the-shelf models including people and object counting, object and sound detection and classification, and biometric authentication. Engage Media Analytics also supports model customization and new model creation.
- Ability to create trigger actions based on insights derived from the media stream whether through other communication capabilities in the EDP, including voice and video calling, creating an on-the-fly conference, sending alerts, and recording, as well as interworking with external systems for initiating business processes in enterprise workflow tools.
- Distributed deployment of services spanning public and private clouds, network edge infrastructure, and on enterprise premises, enabling applications that demand low latency, cost and bandwidth-efficient network utilization for local breakout, and ensuring data privacy and security.
Alan Quayle, Founder TADHack, TADSummit, said: “The programmable communications industry (CPaaS) is evolving from a focus on connectivity to understanding the content of communications through programmable media analytics. Actionable intelligence and compliance are important in delivering innovative new services. The all-in-one Engage Digital Platform delivers AI-based actionable intelligence that enables service providers to deliver business efficiencies for their customers' mission-critical applications.”
Radisys’ Engage Media Analytics can be deployed on distributed edge cloud and integrates with public or private 4G/5G RAN and core network functions such as Network Exposure Function (NEF), abstracting complexities for application developers to productize Industry 4.0 applications quickly and cost-effectively.
Al Balasco, Head of Media and Application Solutions, Radisys, said: “The convergence and simultaneous maturity of multiple technologies like AI-based computer vision, 5G, edge cloud, and programmable communications opens new opportunities for service providers and system integrators to collaborate with enterprises in their digital transformation. Engage Media Analytics lets service providers combine the advantages of the bandwidth, low latency, Internet of Things (IoT) connectivity, and edge cloud resources to monetize public and private 5G networks and deliver customized solutions like predictive surveillance in smart cities, remote monitoring of enterprise campuses, business workflow automation for product quality assurance, traffic monitoring, and more.”
About Radisys
Radisys, a global leader in open telecom solutions, enables service providers to drive disruption with new open architecture business models. Radisys’ innovative disaggregated and virtualized enabling technology solutions leverage open reference architectures and standards, combined with open software and hardware to power business transformation for the telecom industry, while its world-class services organization delivers systems integration expertise necessary to solve communications and content providers’ complex deployment challenges. For more information, visit www.radisys.com.
Radisys’ Engage Digital Platform is an award-winning programmable communications platform. Radisys' capacity-based versus consumption-based licensing approach for all products in the Engage Digital Platform offers a truly disruptive economic model relative to alternative programmable communications solutions. It dramatically improves the total cost of ownership (TCO) savings to 70% and greater over competitive cloud-based programmable communications and video analytics solutions, allowing service providers to reap the benefits.
For more information, visit www.engagedigital.ai.
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230223005336/en/
Contact information
Nereus for Radisys
Matt Baxter, +1-503-619-0505
radisys@nereus-worldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom